Benzinga | Jun 14, 2021 06:53AM EDT

Citigroup Upgrades CRISPR Therapeutics to Neutral, Raises Price Target to $132

Citigroup analyst Yigal Nochomovitz upgrades CRISPR Therapeutics (NASDAQ:CRSP) from Sell to Neutral and raises the price target from $55 to $132.